About the Company
Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, the company knows the need for treatment options is urgent - that is why its global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, Travere continuously seeks to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow.
Employees
262
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TVTX News
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in EuropeConditional marketing authorization is based on ...
Travere Therapeutics Says European Commission Approved Filspari To Treat IgA Nephropathy
(RTTNews) - Travere Therapeutics, Inc., (TVTX) and CSL Vifor Wednesday said the European Commission has granted conditional marketing authorization for Filspari for the treatment of adults with ...
Travere Therapeutics Inc (TVTX) Stock: A Closer Look at the Analyst Ratings
Travere Therapeutics Inc (TVTX) has seen a -10.19% fall in stock performance for the week, with a -16.57% decline in the past month and a -35.10% plunge in the past quarter. The volatility ratio for ...
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
Stay informed and make judicious decisions using our Ratings Table. Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life ...
Travere Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Travere Therapeutics Inc (NASDAQ: TVTX) Stock: A Value Hunter’s Investment?
The trading price of Travere Therapeutics Inc (NASDAQ:TVTX) closed lower on Tuesday, April 02, closing at $7.04, -3.69% lower than its previous close. In examining the 52-week price action we see that ...
Travere Therapeutics Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present eight posters in classical homocystinuria (HCU) at Society for ...
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
Travere Therapeutics, Inc. (NASDAQ: TVTX) and Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that they have entered into a definitive agreement for the sale of Travere’s bile acid ...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment ...
Travere Therapeutics Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Travere Therapeutics Inc (TVTX)
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Loading the latest forecasts...